BML Capital Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 5, 2024), BML Capital Management, LLC reported 29 stock positions worth $169.9 million. Its top holding was iShares 0-3 Month Treasury B (SGOV) at 16.0% of the portfolio, followed by Instil Bio (TIL, 13.3%) and Atea Pharmaceuticals (AVIR, 13.1%). Compared with Q2 2024, it opened 4 new positions, sold out of 2, added to 11 and reduced 6. The biggest buy was a new position in AN2 Therapeutics (ANTX) and the biggest sale SS SPDR BB 1-3M T-Bill ETF (BIL, shares −13%).
- Most Recent 13F
- Q2 2026
- Location
- ZIONSVILLE, IN
- CIK
- 0001616824
- Portfolio Value
- $169.9M (Q3 2024)
- SEC Filing
- 0001754960-24-000545 ↗ filed Nov 5, 2024
Holdings Value
Holdings 29 stocks · $169.9M
| SGOV iShares 0-3 Month Treasury B | 16.00% | 270,000 | $27.2M | No change |
| TIL Instil Bio Inc. | 13.27% | 335,000 | $22.6M | Reduce -14.3% |
| AVIR Atea Pharmaceuticals Inc. | 13.11% | 6,650,000 | $22.3M | Add +4.3% |
| ACRS Aclaris Therapeutics Inc. | 9.64% | 14,250,000 | $16.4M | Add +9.7% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 9.45% | 175,000 | $16.1M | Reduce -12.5% |
| ADVM Adverum Biotechnologies Inc. | 9.37% | 2,268,064 | $15.9M | Add +15.4% |
| TECX Tectonic Therapeutic Inc. | 3.78% | 211,752 | $6.4M | Reduce -54.6% |
| ANTX AN2 Therapeutics Inc. | 3.62% | 5,749,432 | $6.2M | New |
| RENEO PHARMACEUTICALS INC | 3.46% | 3,457,395 | $5.9M | Add +29.4% |
| ORMP Oramed Pharmaceuticals Inc. | 3.14% | 2,186,191 | $5.3M | Add +62.1% |
| ACHL Achilles Therapeutics PL-ADR | 2.46% | 4,100,002 | $4.2M | Add +555.8% |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 2.42% | 2,000,000 | $4.1M | New |
| CNTB Connect Biopharma Hldgs Ltd. | 1.77% | 2,093,232 | $3.0M | Add +2.5% |
| PMVP PMV Pharmaceuticals Inc. | 1.48% | 1,688,772 | $2.5M | Add +29.0% |
| ASTC Astrotech Corp. | 1.04% | 220,410 | $1.8M | No change |
| MIST Milestone Pharmaceuticals Inc. | 1.02% | 1,136,091 | $1.7M | Add +3.0% |
| LENZ Lenz Therapeutics Inc. | 0.84% | 60,000 | $1.4M | Reduce -6.1% |
| IKENA ONCOLOGY INC | 0.74% | 723,288 | $1.3M | Add +23.6% |
| VNDA Vanda Pharmaceuticals Inc. | 0.63% | 228,500 | $1.1M | Reduce -42.6% |
| LSTA Lisata Therapeutics Inc. | 0.50% | 284,669 | $854K | No change |
| PIERIS PHARMACEUTICALS INC | 0.41% | 42,130 | $699K | New |
| CALC Calcimedica Inc. | 0.40% | 153,887 | $682K | Reduce -4.1% |
| ALLOVIR INC | 0.29% | 603,086 | $488K | No change |
| TLIS Talis Biomedical Corp. | 0.27% | 248,702 | $460K | Add +481.9% |
| VTGN Vistagen Therapeutics Inc. | 0.27% | 150,000 | $452K | No change |
| FBRX Forte Biosciences Inc. | 0.23% | 70,468 | $394K | No change |
| NXTC Nextcure Inc. | 0.22% | 276,465 | $379K | No change |
| VRCA Verrica Pharmaceuticals Inc. | 0.15% | 180,000 | $261K | No change |
| HLVX Hillevax Inc. | 0.02% | 19,760 | $35K | New |
Portfolio Sells Q2 2024 → Q3 2024
| BIL SS SPDR BB 1-3M T-Bill ETF | Reduce -12.5% | 9.45% | −3.99 |
| TECX Tectonic Therapeutic Inc. | Reduce -54.6% | 3.78% | −1.85 |
| ATHIRA PHARMA INC | Sold out | 0.00% | −1.75 |
| DSGN Design Therapeutics Inc. | Sold out | 0.00% | −1.03 |
| VNDA Vanda Pharmaceuticals Inc. | Reduce -42.6% | 0.63% | −1.02 |
| CALC Calcimedica Inc. | Reduce -4.1% | 0.40% | −0.06 |
| LENZ Lenz Therapeutics Inc. | Reduce -6.1% | 0.84% | +0.03 |
| TIL Instil Bio Inc. | Reduce -14.3% | 13.27% | +10.32 |
Portfolio Buys Q2 2024 → Q3 2024
| ANTX AN2 Therapeutics Inc. | New | 3.62% | +3.62 |
| WHWK Whitehawk Therapeutics Inc. | New | 2.42% | +2.42 |
| ACHL Achilles Therapeutics PL-ADR | Add +555.8% | 2.46% | +2.09 |
| ORMP Oramed Pharmaceuticals Inc. | Add +62.1% | 3.14% | +0.60 |
| RENEO PHARMACEUTICALS INC | Add +29.4% | 3.46% | +0.50 |
| PIERIS PHARMACEUTICALS INC | New | 0.41% | +0.41 |
| IKENA ONCOLOGY INC | Add +23.6% | 0.74% | +0.03 |
| HLVX Hillevax Inc. | New | 0.02% | +0.02 |
| TLIS Talis Biomedical Corp. | Add +481.9% | 0.27% | −0.00 |
| MIST Milestone Pharmaceuticals Inc. | Add +3.0% | 1.02% | −0.05 |
| PMVP PMV Pharmaceuticals Inc. | Add +29.0% | 1.48% | −0.07 |
| CNTB Connect Biopharma Hldgs Ltd. | Add +2.5% | 1.77% | −0.50 |
| ADVM Adverum Biotechnologies Inc. | Add +15.4% | 9.37% | −0.51 |
| ACRS Aclaris Therapeutics Inc. | Add +9.7% | 9.64% | −0.82 |
| AVIR Atea Pharmaceuticals Inc. | Add +4.3% | 13.11% | −2.35 |
Options Activity Q2 2024 → Q3 2024
| WING Wingstop Inc. | put | Sold out | 714 | $3.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $175.1M | ACRS, AVIR, ENGN, KHC, OM |
| Q1 2026 | 15 | $155.4M | ACRS, AVIR, ORMP, TLYS, OM |
| Q4 2025 | 13 | $113.0M | ACRS, AVIR, ORMP, TIL, PMVP |
| Q3 2025 | 19 | $108.7M | ACRS, AVIR, ADVM, TIL, ORMP |
| Q2 2025 | 23 | $130.5M | AVIR, THRD, ACRS, TIL, EPIX |
| Q1 2025 | 27 | $123.6M | AVIR, ACRS, THRD, ADVM, ANTX |
| Q4 2024 | 25 | $161.0M | ACRS, SGOV, AVIR, ADVM, ANTX |
| Q3 2024 | 29 | $169.9M | SGOV, TIL, AVIR, ACRS, BIL |
| Q2 2024 | 27 | $136.5M | SGOV, AVIR, BIL, ACRS, ADVM |
| Q1 2024Amended | 30 | $149.4M | SGOV, AVIR, BIL, ADVM, ACRS |